Are there any serious side effects of Riflimab? Analysis of common adverse reactions

Retifanlimab-Zynyz is a type of PD-1 immune checkpoint inhibitor. Its side effects are mainly due to its immune activation mechanism. It is different from the extensive toxicity caused by traditional chemotherapy and focuses more on adverse reactions mediated by the immune system. Riflimab was well tolerated, and most side effects were mild to moderate, reversible, and manageable. However, because the drug broadly activates the immune system by relieving T cell suppression, typical immune-related adverse events (irAEs) may still occur in some patients.

Common side effects include rash, fatigue, itching, diarrhea, fever, muscle or joint pain, etc. They usually appear in the early stages of medication and can be relieved after short-term symptomatic treatment. What needs to be more vigilant are some moderate to severe immunoreactive toxicities, such as immune-related pneumonia, enteritis, hepatitis, thyroid dysfunction, etc. Although the incidence of such adverse reactions is not high, once they occur, the drug needs to be stopped immediately and combined with glucocorticoids for intervention to prevent more serious complications.

In addition, some patients also experience transient hemogram abnormalities, elevated liver enzymes, or fluctuations in renal function. Laboratory indicators need to be monitored regularly before medication and during treatment to promptly assess the risk of adverse reactions. Compared with other PD-1 drugs of the same class, refulimab did not show a higher toxicity burden, and its safety profile was similar to existing drugs such as nivolumab or pembrolizumab. Current clinical practice recommends that Zynyz should be used under the guidance of doctors with experience in immunotherapy management, and patients' response to treatment should be closely monitored, and immunotoxicity should be identified and dealt with in a timely manner to ensure efficacy while reducing treatment-related harm.

Overall, as long as the treatment regimen is strictly followed and monitoring and intervention are carried out, the adverse reactions of Riflimab can be effectively controlled, and its safety is within the acceptable range among immunotherapy drugs. It is especially suitable for patients with advanced and advanced solid tumors to try mid- and long-term immune control treatments.

Reference materials:https://www.drugs.com/mtm/retifanlimab.html